XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
1.280
-0.020 (-1.54%)
May 13, 2025, 12:22 PM - Market open

XTL Biopharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-1.03-1.78-1.350.44-2.95
Upgrade
Depreciation & Amortization
0.2-000
Upgrade
Loss (Gain) From Sale of Investments
-0.171.021.53-0.75-0.14
Upgrade
Stock-Based Compensation
0.2600.010.040.05
Upgrade
Other Operating Activities
-1.08-0.01-1.08-0.722.15
Upgrade
Change in Accounts Receivable
0.04----
Upgrade
Change in Accounts Payable
0.210.02-0.04-0.020.02
Upgrade
Change in Other Net Operating Assets
-0.060.050.03-0.030.02
Upgrade
Operating Cash Flow
-1.62-0.71-0.9-1.05-0.85
Upgrade
Capital Expenditures
-0.05----0
Upgrade
Cash Acquisitions
-0.41----
Upgrade
Investment in Securities
-0.01----
Upgrade
Other Investing Activities
0.030.040.040.010.03
Upgrade
Investing Cash Flow
-0.840.040.040.010.03
Upgrade
Long-Term Debt Repaid
-0.01----
Upgrade
Net Debt Issued (Repaid)
-0.01----
Upgrade
Issuance of Common Stock
1.46--0.39-
Upgrade
Financing Cash Flow
1.45--0.39-
Upgrade
Foreign Exchange Rate Adjustments
-0.02-0.03-0.01-0.01-0.01
Upgrade
Net Cash Flow
-1.03-0.69-0.88-0.66-0.82
Upgrade
Free Cash Flow
-1.67-0.71-0.9-1.05-0.85
Upgrade
Free Cash Flow Margin
-370.73%----
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00
Upgrade
Levered Free Cash Flow
0.74-0.41-0.55-0.66-0.5
Upgrade
Unlevered Free Cash Flow
0.76-0.41-0.55-0.66-0.5
Upgrade
Change in Net Working Capital
-1.71-0.060.020.05-0.05
Upgrade
Updated Dec 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q